Combined effect of tumor necrosis factor-alpha and ionizing radiation on the induction of apoptosis in 5637 bladder carcinoma cells

Strahlentherapie und Onkologie

Volumn 182, Issue 8, 2006, Pages 467-472

  Baierlein, Sammy A ^b   Distel, Luitpold ^b   Sieber, Renate ^b   Weiss, Christian ^b   Rödel, Claus ^b   Sauer, Rolf ^b   Rödel, Franz ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b University of Erlangen Nuremberg ^*

Author keywords

Apoptosis; Irradiation; Isobologram analysis; TNF ; Urinary bladder carcinoma cells

Indexed keywords

CYTOKINE; DEATH RECEPTOR; FAS ANTIGEN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CARCINOMA CELL; CELL SURVIVAL; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IONIZING RADIATION; MITOCHONDRION; NICK END LABELING; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIOSENSITIZATION;

APOPTOSIS; CELL LINE, TUMOR; COLONY-FORMING UNITS ASSAY; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IN SITU NICK-END LABELING; RADIOTHERAPY DOSAGE; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; TUMOR STEM CELL ASSAY; URINARY BLADDER NEOPLASMS;

EID: 33747067724     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-006-1475-2     Document Type: Article

References (35)

1. Abend M. Reasons to reconsider the significance of apoptosis for cancer therapy. Int J Radiat Biol 2003;79:927-41.
2. Azria D, Larbouret C, Garambois V, et al. A bispecific antibody to enhance radiotherapy by tumor necrosis factor-alpha in human CEA-expressing digestive tumors. Int J Radiat Oncol Biol Phys 2004;58:580-8.
3. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11:372-7.
4. Belka C, Marini P, Jendrossek V, et al. Death inducing ligands in combination with ionizing radiation: objective and current knowledge. Strahlenther Onkol 2003;179:141-51.
5. Belka C, Rudner J, Wesselborg S, et al. Differential role of caspase-8 and BID activation during radiation and CD95-induced apoptosis. Oncogene 2000;19:1181-90.
6. Burdak-Rothkamm S, Rübe CE, Nguyen TP, et al. Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa®). Strahlenther Onkol 2005;181:197-204.
7. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991;285:199-212.
8. Goyal L. Cell death inhibition: keeping caspases in check. Cell 2001;104:805-8.
9. Gridley DS, Glisson WC, Uhm JR. Interaction of tumour necrosis factor-alpha and radiation against human colon tumour cells. Ther Immunol 1994;1:25-31.
10. Gridley DS, Hammond SN, Liwnicz BH. Tumor necrosis factor-alpha augments radiation effects against human colon tumor xenografts. Anticancer Res 1994;14:1107-12.
11. Hanahan D , Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
12. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
13. Herskind C, Fleckenstein K, Lohr J, et al. Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: Radiobiological and immunologic strategies. Strahlenther Onkol 2004;180:331-9.
14. Jaattela M. Escaping cell death: survival proteins in cancer. Exp Cell Res 1999;248:30-43.
15. Jackson AM, Prescott S, James K. Production of urinary tumour necrosis factors and soluble tumour necrosis factor receptors in bladder cancer patients and bacillus Calmette-Guérin immunotherapy. Cancer Immunol Immunother 1995;40:119-24.
16. Kataoka T. The caspase-8 modulator c-FLIP. Crit Rev Immunol 2005;25:31-58.
17. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
18. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000;6:513-9.
19. Kucharczak J, Simmons MJ, Fan Y, et al. To be, or not to be: NF-kappaB is the answer - role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003;22:8961-82.
20. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89.
21. Luo X, Budihardjo I, Zou H, et al. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481-90.
22. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976;116:180-3.
23. Ning S, Fuessel S, Kotzsch M, et al. siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 2004;25:1065-71.
24. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004;23:2797-808.
25. Oya N, Zolzer F, Werner F, et al. Effects of serum starvation on radiosensitivity, proliferation and apoptosis in four human tumor cell lines with different p53 status. Strahlenther Onkol 2003;179:99-106.
26. Rödel C. Current status of radiation therapy and combined-modality treatment for bladder cancer. Strahlenther Onkol 2004;180:701-9.
27. Rödel C, Grabenbauer GG, Papadopoulos T, et al. Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 2002;52:294-303.
28. Rödel C, Grabenbauer GG, Rödel F, et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 2000;46:1213-21.
29. Schenkman E, Lamm DL. Superficial bladder cancer therapy. Sci World J 2004;4:Suppl 1:387-99.
30. Steel GG. The case against apoptosis. Acta Oncol 2001;40:968-75.
31. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979;5:85-91.
32. Stroh C, Schulze-Osthoff K. Death by a thousand cuts: an ever increasing list of caspase substrates. Cell Death Differ 1998;5:997-1000.
33. Terlikowski SJ. Local immunotherapy with rhTNF-alpha mutein induces strong antitumor activity without overt toxicity - a review. Toxicology 2002;174:143-52.
34. Vandenabeele P, Declercq W, Beyaert R, et al. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995;5:392-9.
35. Weiss C, Rödel F, Wolf I, et al. Combined-modality treatment and organ preservation in bladder cancer. Do molecular markers predict outcome? Strahlenther Onkol 2005;181:213-22.